210 related articles for article (PubMed ID: 19669174)
1. Reactivity of platinum-based antitumor drugs towards a Met- and His-rich 20mer peptide corresponding to the N-terminal domain of human copper transporter 1.
Wu Z; Liu Q; Liang X; Yang X; Wang N; Wang X; Sun H; Lu Y; Guo Z
J Biol Inorg Chem; 2009 Nov; 14(8):1313-23. PubMed ID: 19669174
[TBL] [Abstract][Full Text] [Related]
2. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells.
Song IS; Savaraj N; Siddik ZH; Liu P; Wei Y; Wu CJ; Kuo MT
Mol Cancer Ther; 2004 Dec; 3(12):1543-9. PubMed ID: 15634647
[TBL] [Abstract][Full Text] [Related]
3. The reaction of a platinated methionine motif of CTR1 with cysteine and histidine is dependent upon the type of precursor platinum complex.
Ma G; Wu Q; Wu X; Arnesano F; Natile G; Sletten E; Liu Y
J Inorg Biochem; 2015 Dec; 153():239-246. PubMed ID: 26235215
[TBL] [Abstract][Full Text] [Related]
4. Interaction between platinum complexes and the C-terminal motif of human copper transporter 1.
Wang E; Xi Z; Li Y; Li L; Zhao L; Ma G; Liu Y
Inorg Chem; 2013 May; 52(10):6153-9. PubMed ID: 23642142
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin stabilizes a multimeric complex of the human Ctr1 copper transporter: requirement for the extracellular methionine-rich clusters.
Guo Y; Smith K; Petris MJ
J Biol Chem; 2004 Nov; 279(45):46393-9. PubMed ID: 15326162
[TBL] [Abstract][Full Text] [Related]
6. Coordination of platinum therapeutic agents to met-rich motifs of human copper transport protein1.
Crider SE; Holbrook RJ; Franz KJ
Metallomics; 2010 Jan; 2(1):74-83. PubMed ID: 21072377
[TBL] [Abstract][Full Text] [Related]
7. Electrospray ionization multi-stage mass spectrometric study of the interaction products of the cytotoxic complex [Cu(thp)₄][PF₆] with methionine-rich model peptides.
Peruzzo V; Tisato F; Porchia M; Santini C; Pellei M; Traldi P
Rapid Commun Mass Spectrom; 2015 Feb; 29(3):253-62. PubMed ID: 26411623
[TBL] [Abstract][Full Text] [Related]
8. Platinum transfer from hCTR1 to Atox1 is dependent on the type of platinum complex.
Wu X; Yuan S; Wang E; Tong Y; Ma G; Wei K; Liu Y
Metallomics; 2017 May; 9(5):546-555. PubMed ID: 28383086
[TBL] [Abstract][Full Text] [Related]
9. A re-evaluation of the role of hCTR1, the human high-affinity copper transporter, in platinum-drug entry into human cells.
Ivy KD; Kaplan JH
Mol Pharmacol; 2013 Jun; 83(6):1237-46. PubMed ID: 23543413
[TBL] [Abstract][Full Text] [Related]
10. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B.
Tadini-Buoninsegni F; Bartolommei G; Moncelli MR; Inesi G; Galliani A; Sinisi M; Losacco M; Natile G; Arnesano F
Angew Chem Int Ed Engl; 2014 Jan; 53(5):1297-301. PubMed ID: 24375922
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the high-affinity copper transporter (hCtr1) expression by cisplatin and heavy metals.
Liang ZD; Long Y; Chen HH; Savaraj N; Kuo MT
J Biol Inorg Chem; 2014 Jan; 19(1):17-27. PubMed ID: 24132751
[TBL] [Abstract][Full Text] [Related]
12. Comparison between copper and cisplatin transport mediated by human copper transporter 1 (hCTR1).
Du X; Wang X; Li H; Sun H
Metallomics; 2012 Jul; 4(7):679-85. PubMed ID: 22552365
[TBL] [Abstract][Full Text] [Related]
13. The role of the methionines and histidines in the transmembrane domain of mammalian copper transporter 1 in the cellular accumulation of cisplatin.
Larson CA; Adams PL; Blair BG; Safaei R; Howell SB
Mol Pharmacol; 2010 Sep; 78(3):333-9. PubMed ID: 20519567
[TBL] [Abstract][Full Text] [Related]
14. The roles of copper transporters in cisplatin resistance.
Kuo MT; Chen HH; Song IS; Savaraj N; Ishikawa T
Cancer Metastasis Rev; 2007 Mar; 26(1):71-83. PubMed ID: 17318448
[TBL] [Abstract][Full Text] [Related]
15. Interaction between platinum complexes and a methionine motif found in copper transport proteins.
Arnesano F; Scintilla S; Natile G
Angew Chem Int Ed Engl; 2007; 46(47):9062-4. PubMed ID: 17886318
[No Abstract] [Full Text] [Related]
16. Overcoming platinum drug resistance with copper-lowering agents.
Chen HH; Kuo MT
Anticancer Res; 2013 Oct; 33(10):4157-61. PubMed ID: 24122978
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic comparison of human high-affinity copper transporter 1-mediated transport between copper ion and cisplatin.
Liang ZD; Stockton D; Savaraj N; Tien Kuo M
Mol Pharmacol; 2009 Oct; 76(4):843-53. PubMed ID: 19570948
[TBL] [Abstract][Full Text] [Related]
18. Differences in binding kinetics, bond strength and adduct formation between Pt-based drugs and S- or N-donor groups: A comparative study using mass spectrometry techniques.
Artiaga G; Iglesias-Jiménez A; Moreno-Gordaliza E; Mena ML; Gómez-Gómez MM
Eur J Pharm Sci; 2019 Apr; 132():96-105. PubMed ID: 30844436
[TBL] [Abstract][Full Text] [Related]
19. Modulating Chemosensitivity of Tumors to Platinum-Based Antitumor Drugs by Transcriptional Regulation of Copper Homeostasis.
Lai YH; Kuo C; Kuo MT; Chen HHW
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29772714
[TBL] [Abstract][Full Text] [Related]
20. Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy.
Kuo MT; Fu S; Savaraj N; Chen HH
Cancer Res; 2012 Sep; 72(18):4616-21. PubMed ID: 22962276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
